» Articles » PMID: 33207021

Skin Manifestations of COVID-19 in Children: Part 3

Abstract

The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestations of COVID-19, chilblain-like lesions, and in Part 2 we expanded to other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome. In this part of the review, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children for both COVID-19 and any other pre-existing conditions.

Citing Articles

Defining the short-term and long-term skin manifestations of COVID-19: insights after more than three years of the pandemic.

Ica O, Mitroi G, Ianosi S, Tutunaru C, Leru P, Matei D Rom J Morphol Embryol. 2023; 64(3):291-304.

PMID: 37867347 PMC: 10720941. DOI: 10.47162/RJME.64.3.01.


COVID-19 Associated Vasculitis Confirmed by the Tissues RT-PCR: A Case Series Report.

Belozerov K, Avrusin I, Andaryanova L, Guseva A, Shogenova Z, Belanovich I Biomedicines. 2023; 11(3).

PMID: 36979849 PMC: 10046188. DOI: 10.3390/biomedicines11030870.


Dermatopathology of COVID-19 infection and vaccination.

Fernandez-Figueras M Pathologie (Heidelb). 2022; 43(Suppl 1):114-118.

PMID: 36197514 PMC: 9533285. DOI: 10.1007/s00292-022-01126-9.


Does Multisystem Inflammatory Syndrome Only Mimic Acute Appendicitis in Children or Can It Coexist: When Should We Suspect MIS-C?.

Vanseviciene I, Krunkaityte U, Dekeryte I, Berzanskis M, Lukosiute-Urboniene A, Malcius D Medicina (Kaunas). 2022; 58(8).

PMID: 36013568 PMC: 9416076. DOI: 10.3390/medicina58081101.


Evolving Skin Rash as a Rare Cutaneous Manifestation in a Pediatric Patient With COVID-19 Infection.

Tilak K, Joung K, Apath M Cureus. 2022; 14(6):e26477.

PMID: 35919370 PMC: 9339118. DOI: 10.7759/cureus.26477.


References
1.
Kaya G, Kaya A, Saurat J . Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature. Dermatopathology (Basel). 2020; 7(1):3-16. PMC: 7583593. DOI: 10.3390/dermatopathology7010002. View

2.
Brunasso A, Massone C . Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during COVID-19 emergency in a tertiary center in Italy. Dermatol Ther. 2020; 33(4):e13495. PMC: 7267078. DOI: 10.1111/dth.13695. View

3.
Wang C, Rademaker M, Baker C, Foley P . COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement. Australas J Dermatol. 2020; 61(3):210-216. PMC: 7262046. DOI: 10.1111/ajd.13313. View

4.
Ricardo J, Lipner S . Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther. 2020; 33(5):e13687. PMC: 7283778. DOI: 10.1111/dth.13687. View

5.
Marasca C, Ruggiero A, Napolitano M, Fabbrocini G, Megna M . May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions?. Med Hypotheses. 2020; 143:109853. PMC: 7236705. DOI: 10.1016/j.mehy.2020.109853. View